Literature DB >> 27956700

mTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.

Deborah Silvera1, Amanda Ernlund1, Rezina Arju1, Eileen Connolly1, Viviana Volta1, Jinhua Wang2, Robert J Schneider3,2.   

Abstract

mTOR coordinates growth signals with metabolic pathways and protein synthesis and is hyperactivated in many human cancers. mTOR exists in two complexes: mTORC1, which stimulates protein, lipid, and ribosome biosynthesis, and mTORC2, which regulates cytoskeleton functions. While mTOR is known to be involved in the DNA damage response, little is actually known regarding the functions of mTORC1 compared to mTORC2 in this regard or the respective impacts on transcriptional versus translational regulation. We show that mTORC1 and mTORC2 are both required to enact DNA damage repair and cell survival, resulting in increased cancer cell survival during DNA damage. Together mTORC1 and -2 enact coordinated transcription and translation of protective cell cycle and DNA replication, recombination, and repair genes. This coordinated transcriptional-translational response to DNA damage was not impaired by rapalog inhibition of mTORC1 or independent inhibition of mTORC1 or mTORC2 but was blocked by inhibition of mTORC1/2. Only mTORC1/2 inhibition reversed cancer cell resistance to DNA damage and replicative stress and increased tumor cell killing and tumor control by DNA damage therapies in animal models. When combined with DNA damage, inhibition of mTORC1/2 blocked transcriptional induction more strongly than translation of DNA replication, survival, and DNA damage response mRNAs.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  DNA damage; DNA damage response; breast cancer; mTOR; protein synthesis; transcriptional control; translational control

Mesh:

Substances:

Year:  2017        PMID: 27956700      PMCID: PMC5311240          DOI: 10.1128/MCB.00577-16

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

1.  Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.

Authors:  Haiyan Li; Jun Lin; Xiaokai Wang; Guangyu Yao; Liping Wang; Hang Zheng; Cuilan Yang; Chunhong Jia; Anling Liu; Xiaochun Bai
Journal:  Breast Cancer Res Treat       Date:  2012-04-04       Impact factor: 4.872

2.  The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

Authors:  Iwan Beuvink; Anne Boulay; Stefano Fumagalli; Frederic Zilbermann; Stephan Ruetz; Terence O'Reilly; Francois Natt; Jonathan Hall; Heidi A Lane; George Thomas
Journal:  Cell       Date:  2005-03-25       Impact factor: 41.582

Review 3.  mTOR signaling and drug development in cancer.

Authors:  Janet Dancey
Journal:  Nat Rev Clin Oncol       Date:  2010-03-16       Impact factor: 66.675

4.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.

Authors:  S Matsuoka; G Rotman; A Ogawa; Y Shiloh; K Tamai; S J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

5.  mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression.

Authors:  F Guo; J Li; S Zhang; W Du; S Amarachintha; J Sipple; J Phelan; H L Grimes; Y Zheng; Q Pang
Journal:  Leukemia       Date:  2013-07-15       Impact factor: 11.528

Review 6.  Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression.

Authors:  Diane C Fingar; John Blenis
Journal:  Oncogene       Date:  2004-04-19       Impact factor: 9.867

7.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Authors:  Ker Yu; Lourdes Toral-Barza; Celine Shi; Wei-Guo Zhang; Judy Lucas; Boris Shor; Jamie Kim; Jeroen Verheijen; Kevin Curran; David J Malwitz; Derek C Cole; John Ellingboe; Semiramis Ayral-Kaloustian; Tarek S Mansour; James J Gibbons; Robert T Abraham; Pawel Nowak; Arie Zask
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

8.  G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.

Authors:  Ning Gao; Daniel C Flynn; Zhuo Zhang; Xiao-Song Zhong; Valerie Walker; Ke Jian Liu; Xianglin Shi; Bing-Hua Jiang
Journal:  Am J Physiol Cell Physiol       Date:  2004-03-17       Impact factor: 4.249

9.  TOR complex 2 controls gene silencing, telomere length maintenance, and survival under DNA-damaging conditions.

Authors:  Miriam Schonbrun; Dana Laor; Luis López-Maury; Jürg Bähler; Martin Kupiec; Ronit Weisman
Journal:  Mol Cell Biol       Date:  2009-06-22       Impact factor: 4.272

Review 10.  The comet assay for DNA damage and repair: principles, applications, and limitations.

Authors:  Andrew R Collins
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.860

View more
  18 in total

1.  Regenerative proliferation of differentiated cells by mTORC1-dependent paligenosis.

Authors:  Spencer G Willet; Mark A Lewis; Zhi-Feng Miao; Dengqun Liu; Megan D Radyk; Rebecca L Cunningham; Joseph Burclaff; Greg Sibbel; Hei-Yong G Lo; Valerie Blanc; Nicholas O Davidson; Zhen-Ning Wang; Jason C Mills
Journal:  EMBO J       Date:  2018-02-21       Impact factor: 11.598

Review 2.  Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.

Authors:  Tzu-Ting Huang; Erika J Lampert; Cynthia Coots; Jung-Min Lee
Journal:  Cancer Treat Rev       Date:  2020-04-10       Impact factor: 12.111

3.  Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells.

Authors:  Sameer S Chopra; Anne Jenney; Adam Palmer; Mario Niepel; Mirra Chung; Caitlin Mills; Sindhu Carmen Sivakumaren; Qingsong Liu; Jia-Yun Chen; Clarence Yapp; John M Asara; Nathanael S Gray; Peter K Sorger
Journal:  Cell Syst       Date:  2019-12-04       Impact factor: 10.304

4.  Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity.

Authors:  Stacey L Lehman; Theresa Wechsler; Kayla Schwartz; Lauren E Brown; John A Porco; William G Devine; Jerry Pelletier; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Ther       Date:  2022-09-06       Impact factor: 6.009

5.  RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair.

Authors:  Rui Gou; Xiao Li; Hui Dong; Yuexin Hu; Ouxuan Liu; Juanjuan Liu; Bei Lin
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

6.  DNA-PK promotes activation of the survival kinase AKT in response to DNA damage through an mTORC2-ECT2 pathway.

Authors:  Liu Liu; Xiaoming Dai; Shasha Yin; Pengda Liu; Elizabeth G Hill; Wenyi Wei; Wenjian Gan
Journal:  Sci Signal       Date:  2022-01-04       Impact factor: 9.517

7.  Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming.

Authors:  Phillip A Geter; Amanda W Ernlund; Sofia Bakogianni; Amandine Alard; Rezina Arju; Shah Giashuddin; Abhilash Gadi; Jacqueline Bromberg; Robert J Schneider
Journal:  Genes Dev       Date:  2017-12-21       Impact factor: 11.361

Review 8.  The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.

Authors:  Jessica Lawrence; Richard Nho
Journal:  Int J Mol Sci       Date:  2018-03-08       Impact factor: 5.923

9.  Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.

Authors:  Tzu-Ting Huang; Ethan Brill; Jayakumar R Nair; Xiaohu Zhang; Kelli M Wilson; Lu Chen; Craig J Thomas; Jung-Min Lee
Journal:  Cancer Res       Date:  2020-09-30       Impact factor: 13.312

10.  AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors.

Authors:  Kavya Ramkumar; C Allison Stewart; Kasey R Cargill; Carminia M Della Corte; Qi Wang; Li Shen; Lixia Diao; Robert J Cardnell; David H Peng; B Leticia Rodriguez; You-Hong Fan; John V Heymach; Jing Wang; Carl M Gay; Don L Gibbons; Lauren A Byers
Journal:  Mol Cancer Res       Date:  2020-11-10       Impact factor: 6.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.